Previous 10 | Next 10 |
2024-03-13 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 18:15:02 ET Wedbush analyst issues BUY recommendation for LQDA on March 13, 2024 05:00PM ET. The previous analyst recommendation was Buy. LQDA was trading at $14.73 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-03-13 18:15:01 ET Needham analyst issues UNDERPERFORM recommendation for LQDA on March 13, 2024 05:00PM ET. The previous analyst recommendation was Underperform. LQDA was trading at $14.73 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-03-13 14:40:02 ET Liquidia Corporation (LQDA) Q4 2023 Earnings Conference Call March 13, 2024, 8:30 a.m. ET Company Participants Roger Jeffs - CEO Scott Moomaw - CCO Michael Kaseta - COO & CFO Rajeev Saggar - CMO Jason Adair - CBO Rusty Schun...
SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...
2024-03-13 06:03:14 ET More on Liquidia Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia says FDA review for...
Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approval Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid Advancing industry leading portfolio for inhaled treprostinil with YUT...
2024-03-12 11:22:10 ET More on Liquidia Liquidia Corporation: A Complicated Tale Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia says FDA review for...
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a cor...
2024-03-03 10:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Liquidia Technologies Inc. Company Name:
LQDA Stock Symbol:
NASDAQ Market:
Liquidia Technologies Inc. Website:
2024-07-12 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues PERFORM recommendation for LQDA on June 24, 2024 04:14PM ET. LQDA was trading at $12.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommendat...
Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liqui...